XBIO
Xenetic Biosciences, Inc.
$3.09
0.00%
$7.1M
No data for this timeframe.
Vol
Market Cap$7.1M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$387.4K
Inst. Activity2 buys / 1 sells
SEC Reports3
Recent Activity
May 13, 2026
SEC
Xenetic Biosciences reported Q1 2026 results with royalty revenue up 36% YoY to ~$0.8M and net loss narrowing 49% to ~$0
8-K — Impact 3/10
May 11, 2026
earnings_calendar
XBIO Q1 2026 Earnings Scheduled — 2026-05-11
Apr 24, 2026
SEC
Xenetic Biosciences filed an amended 10-K to include Part III disclosures (Items 10-14) on directors, executive compensa
10-K/A — Impact 3/10
Apr 24, 2026
SEC
Xenetic Biosciences granted 100,000 restricted shares to its Interim CEO and CFO, James Parslow, with 7,000 shares vesti
8-K — Impact 3/10
Apr 21, 2026
Insider
PARSLOW JAMES F sold 100,000 shares
Interim CEO and CFO @ $0.00 ($0.00)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
178,509 shares ($387.4K)
Inst.
BANK OF AMERICA CORP — ADD
18 shares ($39.00)
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 9, 2025 | HC Wainwright & Co. | REITERATE | Neutral → Neutral |
| Mar 20, 2025 | HC Wainwright & Co. | REITERATE | Neutral → Neutral |
| Dec 5, 2024 | HC Wainwright & Co. | REITERATE | Neutral → Neutral |
| Nov 22, 2024 | HC Wainwright & Co. | REITERATE | Neutral |
| Aug 20, 2024 | HC Wainwright & Co. | REITERATE | Neutral |
Latest Reports
NEUTRAL
8-K
3/10
Xenetic Biosciences reported Q1 2026 results with royalty revenue up 36% YoY to ~$0.8M and net loss narrowing 49% to ~$0
May 13, 2026
NEUTRAL
10-K/A
3/10
Xenetic Biosciences filed an amended 10-K to include Part III disclosures (Items 10-14) on directors, executive compensa
Apr 24, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $387.4K | DOUBLED |
| BANK OF AMERICA CORP | $39.00 | ADD |
| MORGAN STANLEY | $7.00 | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 21, 2026 | PARSLOW JAMES | A | $0.00 |
3 institutional holders with $387.4K total value (178,530 shares) as of 2025-Q4. Top holders: RENAISSANCE, BANK, MORGAN. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 178,509 | $387.4K | 100.0% | DOUBLED +516.6% |
| 2 | BANK OF AMERICA CORP /DE/ | 18 | $39.00 | 0.0% | ADD +50.0% |
| 3 | MORGAN STANLEY | 3 | $7.00 | 0.0% | TRIM -25.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 28,950 | 178,509 | +516.6% | $387.4K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 12 | 18 | +50.0% | $39.00 | 2025-Q4 |
| MORGAN STANLEY | TRIM | 4 | 3 | -25.0% | $7.00 | 2025-Q4 |
| CITADEL ADVISORS LLC | ADD | 13,380 | 17,289 | +29.2% | $45.1K | 2025-Q1 |
| UBS Group AG | ADD | 1,656 | 2,531 | +52.8% | $6.6K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 1 | 4 | +300.0% | $11.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 15,850 | 25,550 | +61.2% | $101.9K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEW | — | 13,380 | — | $53.9K | 2024-Q4 |
1 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 21, 2026 | PARSLOW JAMES F | Interim CEO and CFO | A | 100,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 3.0/10.
NEUTRAL
8-K
3/10
Xenetic Biosciences reported Q1 2026 results with royalty revenue up 36% YoY to ~$0.8M and net loss
May 13, 2026
NEUTRAL
10-K/A
3/10
Xenetic Biosciences filed an amended 10-K to include Part III disclosures (Items 10-14) on directors
Apr 24, 2026
NEUTRAL
8-K
3/10
Xenetic Biosciences granted 100,000 restricted shares to its Interim CEO and CFO, James Parslow, wit
Apr 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Apr 2025): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 9, 2025 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Mar 20, 2025 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Dec 5, 2024 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Nov 22, 2024 | HC Wainwright & Co. | REITERATE | — | Neutral |
| Aug 20, 2024 | HC Wainwright & Co. | REITERATE | — | Neutral |
| May 16, 2023 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Feb 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Dec 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Nov 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 11, 2026
earnings_calendar
XBIO Q1 2026 Earnings Scheduled — 2026-05-11
Apr 1, 2026
Clinical Trial
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Phase Phase 2 — TERMINATED
Mar 16, 2026
earnings_calendar
XBIO Q4 2025 Earnings After Market Close — 2026-03-16